CORT vs MET · P/E 199, rev $675.0M vs P/E 13, $52.16B cap
Corcept Therapeutics Incorporated (CORT) versus MetLife Inc (MET) — a side-by-side from cached financials, not a winner call.
Corcept Therapeutics Incorporated (CORT) is a biotechnology company listed on US.
MetLife Inc (MET) is a insurance - life company listed on US.
Latest reported CORT revenue for 2024-12-31 was $675.0M. Net income was $141.2M. Revenue was up 39.9% from 2023-12-31 to 2024-12-31. CORT currently screens at market cap $7.46B and trailing P/E 198.5.
MET does not have a complete income-statement cache yet.
CORT currently screens at market cap $7.46B and trailing P/E 198.5. MET currently screens at market cap $52.16B and trailing P/E 12.7.
Not investment advice. Open the CORT and MET stock pages for the full models.
Not investment advice.